Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ali Antar

Urology Madison, WI Medical Doctor

NPI 1770010340 CMS profile 11317635

31 University Houses Apt F, Madison, WI 53705

Open in the dashboard

General payments

$3,805

43 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,289 paid to institutions, not to them · program year 2025

Through program year 2025, Ali Antar of Madison, WI is reported in the CMS Open Payments database as having received $3,805 across 43 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,289 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 58th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,119 8
2024 General $612 7
2023 General $1,458 17
2022 General $616 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Antar
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Ali Antar were reported at $1,119. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Ali Antar Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $616 $476 $143–$1,263 $149
2023 $1,458 $560 $168–$1,461 $160
2024 $612 $563 $170–$1,464 $164
2025 $1,119 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $1,412 19 payments
  2. Calyxo, Inc. $935 5 payments
  3. Teleflex LLC $402 7 payments
  4. Coloplast Corp $297 3 payments
  5. Cook Medical LLC $292 2 payments
  6. PROCEPT BioRobotics Corporation $184 3 payments
  7. Stryker Corporation $166 1 payment
  8. Intuitive Surgical, Inc. $69 1 payment
  9. Medtronic, Inc. $25 1 payment
  10. Progenics Pharmaceuticals, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,376 39 payments
  2. Travel and Lodging $1,430 4 payments
Products named General payments · program years 2022–2025
  1. CVAC ASPIRATION SYSTEM $935 5 payments
  2. UROLIFT $402 7 payments
  3. Titan $297 3 payments
  4. LithoVue $211 4 payments
  5. Moses 550 DFL $206 2 payments
  6. AQUABEAM ROBOTIC SYSTEM $184 3 payments
  7. General - Erectile Dysfunction $170 4 payments
  8. 1688 $166 1 payment
  9. LITHO 150 $153 1 payment
  10. FIBER DUST $139 1 payment
  11. Other $143 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

139

Median for Urology: 1,053

Drug cost

$12,668

Median for Urology: $101,464

Branded share of claims

33.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 18 $10,903
Tamsulosin Hcl Generic 74 $738
Oxybutynin Chloride Er Oxybutynin Chloride Brand 28 $652
Solifenacin Succinate Generic 19 $375

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$65,681

Medicare's payments for the services billed

Medicare patients

307

Average age 72

Services billed

694

74 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 35%
Diabetes 32%
Chronic kidney disease 31%
Ischemic heart disease 29%
Depression 26%
Atrial fibrillation 23%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record